National Human Genome Research Institute (NHGRI)
genome.govTotal trials
203
Active
37
Phase 3
0
Total enrollment
243,408
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 8 of 8 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| ManNAc | — | — | — | — | 3 | ||
| MK-7075 | — | — | — | — | 2 | ||
| Sirolimus | — | — | — | — | — | 2 | |
| AAV9-GLB1 | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 | |
| Methylprednisolone | — | — | — | — | — | 1 | |
| Prednisone | — | — | — | — | — | 1 | |
| Cysteamine | — | — | — | — | — | 1 |
Next readouts
- 2026-07-01
- 2027-11-30
- 2028-01-01
Top conditions
- Diabetes9
- Healthy Volunteers7
- Breast Cancer6
- Cancer5
- Genetic Disease5
- Prostate Cancer4
- Genetics4
- Pregnancy4
Frequently asked questions about National Human Genome Research Institute (NHGRI)
- How many clinical trials does National Human Genome Research Institute (NHGRI) have on ClinicalTrials.gov?
- National Human Genome Research Institute (NHGRI) is listed as the lead sponsor on 203 clinical trials in ClinicalTrials.gov, 37 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Human Genome Research Institute (NHGRI)'s trials are in Phase 3?
- 0 of National Human Genome Research Institute (NHGRI)'s trials are in Phase 3, spread across 8 active drug programs.
- What therapeutic areas does National Human Genome Research Institute (NHGRI) focus on?
- National Human Genome Research Institute (NHGRI)'s most-studied conditions on ClinicalTrials.gov are Diabetes, Healthy Volunteers, Breast Cancer, Cancer, Genetic Disease.
- When are National Human Genome Research Institute (NHGRI)'s next clinical trial readouts?
- National Human Genome Research Institute (NHGRI) has 3 upcoming primary-completion readouts tracked here; the soonest is “MK-7075 (Miransertib) in Proteus Syndrome”, expected around 2026-07-01.